STING1 and neoplasm: In any case, the data that we present here suggest that Palbociclib in combination with inhibitors of factors including AKT1, STING, or IKK may provide an eventual strategy to modulate the SASP-related, inflammatory environment that could augment anti-tumor responses in a context-dependent manner.